Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information

This site is intended for
US residents.

Dosing Tolerability

Dosing tolerability in clinical trials

Low rate of injection site reactions from PRECiSE 1 and PRECiSE 2 (<3%)1,2

  • <1% injection site stinging
  • <1% injection site burning

Low incidence of allergic reactions (<1%)2

  • No anaphylactic shock observed3
  • Other hypersensitivity reactions observed in clinical trials included angioedema and serum sickness

Serious and sometimes fatal side effects have been reported with CIMZIA. These include tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

References:

  1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
  2. Schreiber S, Feagan BG, Hanauer SB, Rutgeerts P, Sandborn WJ. Subcutaneous certolizumab pegol is well tolerated by patients with active Crohn's disease: results from two phase III studies (PRECiSE 1 and 2). Poster presented at: Digestive Disease Week; May 20-25, 2006; Los Angeles, CA.
  3. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA